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gabra2 gene codes for the alpha-2 subunit of the GABAA receptor, one of the ionotropic receptors which
has been related to anxiety, depression and other behavioural disorders, including drug dependence and
schizophrenia. GABAergic signalling also plays a role during development, by promoting neural stem cell
maintenance and renewal. To investigate the role of gabra2 in CNS development, gabra2 deﬁcient zeb-
raﬁsh were generated. The pattern of proliferation during the embryonic development was disrupted in
morphant embryos, which also displayed an increase in the number of apoptotic nuclei mainly at the
mid- and hindbrain regions. The expression of several genes (notch1, pax2, fgf8 and wnt1) known to
contribute to the development of the central nervous system was also affected in gabra2 morpholino-
injected embryos, although no changes were found for pax6a and shh a expression. The transcriptional
activity of neuroD (a proneural gene involved in early neuronal determination) was down-regulated in
gabra2 deﬁcient embryos, and the expression pattern of gad1b (GABA-synthesising enzyme GAD67) was
clearly reduced in injected ﬁsh. I propose that gabra2 might be interacting with those signalling path-
ways that regulate proliferation, differentiation and neurogenesis during the embryonic development;
thus, gabra2 might be playing a role in the differentiation of the mesencephalon and cerebellum. Given
that changes in GABAergic circuits during development have been related to several psychiatric dis-
orders, such as autism and schizophrenia, this work might be helpful to understand the role of neuro-
transmitter systems during CNS development and to assess the developmental effects of several GA-
BAergic drugs.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The γ-aminobutyric acid (GABA) is the main inhibitory neuro-
transmitter in the vertebrate central nervous system (CNS), and
elicits its actions by binding to three different classes of receptors:
the ionotropic receptors GABAA, and GABAC, and the metabotropic
receptors GABAB. [1]. The GABAA receptors are ligand-gated
chloride channels, which usually reduce the membrane excit-
ability by reducing the membrane potential to chloride potentialB.V. This is an open access article u
ﬁbroblast growth factor 8;
tyric acid (GABA) A receptor;
lpha-2; gad1b, glutamate
tu hybridisation; KCC2, neu-
, mid-hindbrain boundary;
mologue 1a; ORF, open
red box gene 2a; shh a, sonic
e family, member 1
stry and Molecular Biology,
tilla y León (INCyL), c/ Pintor(approximately 80 mM in neurons) [2], and thus inhibiting
neurotransmitter release. The prototypical GABAA receptor is
formed by ﬁve protein subunits arranged in a ring, shaping a
central chloride pore. Each subunit contains four transmembrane
α-helices, a C-terminal and a large N-terminal domains, both lo-
cated on the extracellular face of the plasma membrane. There are
different types of subunits that can be combined in several ways to
form a functional GABAA receptor, although most of them contain
two alpha, two beta and one gamma subunit [3]. Different receptor
subtypes display differences in their location, afﬁnity for GABA, the
properties of the chloride channel and in their pharmacology. The
GABAA receptor has one binding site for GABA, its agonists (e.g.
muscimol) and antagonists (e.g. bicuculline) at the α–β subunit
interface, and several other binding sites for different modulators,
as for example benzodiazepines (at the α–γ interface), neuro-
steroids and ethanol [4–7].
Although GABA is an inhibitory neurotransmitter in the adult
brain, there is evidence that it also has an excitatory role during
the CNS development in mammals [8]. In the immature brain,
GABAergic synapses, which are formed prior to the glutamatergicnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of intracellular chloride ions; in this way, GABA keeps immature
neurons in a depolarised state. The transition of GABA signalling
takes place after the expression of the neuron-speciﬁc potassium/
chloride cotransporter 2 (KCC2), which shifts the chloride equili-
brium potential, and then GABAergic synapses become inhibitory
[9,10]. Besides, GABAergic signalling also plays a role in neural
stem cell maintenance and renewal, as stem cells express GABA
receptors and release GABA [11]. It seems that auto/paracrine
GABA action upon GABAA receptors reduces proliferation of neural
stem cells by blocking them in the S phase, but it does not affect
differentiation [12,13]. Pleiotropic effects of GABA signalling dur-
ing brain development include modulation of proliferation and
neuronal maturation. During cortical development, migrating in-
terneurons release GABA, which activates GABAA receptors in the
radial glia, thus reducing progenitor proliferation and the migra-
tion of immature pyramidal neurons. GABA signalling is also re-
quired for dendritic arborisation and synaptogenesis in cortical
neurons. In the subventricular zone, GABA reduces proliferation
and migration of young neurons to the rostral migratory stream. In
the other stem cell niche of the adult brain, GABA release regulates
the synaptic integration and maturation of newborn granule cells
in the dentate gyrus of the hippocampus [14].
The pharmacological interest of GABAA receptor is unques-
tionable, as it is the target of several neuroactive drugs, such as
benzodiazepines, barbiturates, picrotoxine and muscimol. Besides,
GABAA receptor also plays a role in the ethanol-elicited depressor
response [15]. GABAA receptors mediate many behavioural effects
of ethanol, including sedation, reduction in anxiety, motor co-
ordination impairment [16], stimulation of the mesolimbic reward
circuitry [17] and withdrawal symptoms [16]. It has been reported
that the GABAA receptor alpha-2 subunit (gene name, gabra2) is a
key protein in the control of spinal pain, as knock-out mice for
gabra2 gene displayed reduced analgesia after benzodiazepine
administration [18]. This ﬁnding represents a further contribution
to develop novel antinociceptive agents that can speciﬁcally target
this receptor subtype, thus eliciting analgesia but avoiding un-
desirable side-effects. Besides, α2-containing GABAA receptors
have also been linked to anxiety, depression and other behavioural
disorders, including drug dependence and schizophrenia [19].
Evidence from knock-out studies performed in mice indicates that
gabra2 subunit may represent a pharmacological target to develop
antidepressant drugs [20]. Also, several haplotypes of gabra2 gene
have been associated to ethanol, nicotine and cannabis depen-
dence [21,22].
The validation of novel therapeutic agents and their potential
effects on the desired targets requires a straightforward system to
perform in vivo tests. In this line, the zebraﬁsh clearly shows many
advantages [23,24]. It seems that GABA depletion is a common
feature in treatment-resistant seizures, and GABAergic neuro-
transmission could stand for a novel therapeutic target. In this line,
zebraﬁsh seizure model has shown similar behavioural responses
to mice models when treated with anti epileptic drugs [25] and
locomotor assays with zebraﬁsh larvae can be used to screen for
novel anticonvulsant drugs [26]. Edge preference is a behavioural
assay with zebraﬁsh larvae that measures anxiety, and the an-
xiolytic effect of benzodiazepines that bind to GABAA receptors is
reﬂected as a reduction in edge preference [27]. In this work I
analyse the role of the gabra2 gene in the CNS development, and
its potential cross-talk with other morphogen cascades and neu-
rotransmitter systems that control neuronal development. These
ﬁndings might be helpful to evaluate the developmental effects of
several drugs that target the GABAergic system.2. Materials and methods
2.1. Zebraﬁsh maintenance, breeding and drug treatments
The experiments were performed using the wild type AB zeb-
raﬁsh line. General maintenance and care of ﬁsh were carried out
according to standard protocols in our own zebraﬁsh facility. An-
imals were maintained at a constant temperature of 28 °C in a 14 h
light cycle and fed three times a day. Embryos were obtained by
natural mating and cultured in E3 medium, with or without the
addition of 0.003% 1-Phenyl-2-thiourea (PTU, Sigma) to inhibit
pigmentation. Embryos were staged according to hours post fer-
tilisation (hpf) [28]. In all experiments, adequate measures were
taken to minimise pain or discomfort and animals were handled
according to the guidelines of the European Communities Council
Directive 2010/63/UE, to the current Spanish legislation for the use
and care of animals RD 53/2013 (BOE-A-2013-1337) and to the
Guide for the Care and Use of Laboratory animals as adopted and
promulgated by the U.S. National Institutes of Health (2011). All
experiments were performed at the University of Salamanca with
the approval of the University of Salamanca Animal Care
Committee.
Zebraﬁsh embryos were exposed to 1 μM GABA, 1 μM musci-
mol or 100 μM bicuculline in E3 embryo buffer from 5 hpf to
24 hpf. A control group (no drug treatment) was also included for
comparison.
2.2. Cloning
The complete open reading frame (ORF) from gabra2 gene was
cloned using standard procedures and the oligonucleotides de-
scribed in Table S1. Brieﬂy, a partial ORF for gabra2 gene was in-
itially cloned and then the ampliﬁcation of the 5′ unknown se-
quence was achieved by 5′ RACE (5′/3′ RACE Kit, Roche Applied
Science) following the protocol described by the supplier; then
two oligonucleotides were designed to amplify the complete ORF
and subcloned in pCRs4-TOPOs vector (Invitrogen, Life Technol-
ogies). The partial ORF for gad1b was also ampliﬁed and subcloned
into the same vector. To conﬁrm the sequence of the cloned in-
serts, DNA sequencing was performed by the Sequencing Facility
(Servicio de Secuenciación, Universidad de Salamanca, Spain).
These clones were used to generate the corresponding in situ
riboprobes.
2.3. Sequence analysis
Amino acid sequences of Gabra2 proteins from zebraﬁsh (dr –
Danio rerio), human (hs – Homo sapiens), chimpanzee (pt – Pan
troglodytes), cow (bt – Bos taurus), mouse (mm – Mus musculus),
rat (rn – Rattus norvegicus), xenopus (xt – Xenopus tropicalis) and
two other ﬁsh species (tn – Tetraodon nigroviridis and ga – Gas-
terosteus aculeatus) were obtained from the Treefam record of the
family (Database accession number TF315453) and were auto-
matically aligned with MUSCLE [29]. The resulting alignment was
analysed using JalView [30] and the ClustalX colouring scheme
was used. SMART software (http://smart.embl-heidelberg.de/) was
used to perform the protein structure analysis.
2.4. Homology modelling
The 3D structure of Gabra2 subunit from D. rerio was predicted
by homology modelling using Pyhre2 server [31] using the crystal
structure of the human β3 homopentamer of GABRAA receptor
(4COF PDB ID) [32] as template. Phyre2 investigator was run to
perform an in-depth analysis of model quality and conservation,
and benzodiazepine binding domain was predicted by Fpocket
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termined by homology using clustalW alignment with β3, α1, α2
and α6 subunits of human GABAA receptor. The amino acid se-
quence of these subunits was retrieved form UNIPROT. The 3D
modelled structure was visualised and molecular graphics and
analyses were performed with the UCSF Chimera package [34].
2.5. In situ hybridisation
The following riboprobes were used: fgf8 (ﬁbroblast growth
factor 8), gad1b (glutamate decarboxylase GAD67), neuroD (neu-
rogenic differentiation), notch1a (notch homologue 1a), pax2a
(paired box gene 2a), pax6a (paired box gene 2a), shh a (sonic
hedgehog a) and wnt1 (wingless-type MMTV integration site fa-
mily, member 1a). The probes were transcribed from their tem-
plates using the DIG RNA Labelling Kit (SP6/T7) (Roche Applied
Science) following the manufacturer's instructions. In situ hy-
bridisations were performed on wholemounts as previously de-
scribed [35], and probes were detected using BM purple or NBT/
BCIP reagents (Roche Applied Science). Control experiments were
always performed in parallel. Images were taken with a Leica
M165FC Stereomicroscope. 25 embryos were scored for each
treatment and for each time point, and each experiment was re-
peated three times.
2.6. MO injections: knockdown assays at one-cell stage
The translation blocking antisense morpholino GA-
GAATGACCCCGTCGCAGAATCAT complementary to the region from
þ1 to þ25 of the dre-gabra2 ORF was purchased from GeneTools
LLC and was microinjected at the 1-cell stage at a concentration of
0.25 mM. As control, the standard control morpholino (also
available from GeneTools) was injected at the same concentration.
2.7. Immunohistochemistry
Immunohistochemical studies were performed either on
wholemounts or on cryosections and analysed with Leica M165FC
Stereomicroscope or with an Olympus AX70 ﬂuorescence micro-
scope. In some cases, images were taken with a confocal micro-
scope (Leica microsystems). The rabbit anti-histone H3 (phospho
Ser10, Abcam Cat# ab5176, RRID:AB_304763) was used as primary
antibody (1:100) and Alexa Fluor 594 conjugated anti-rabbit
(Molecular Probes (Invitrogen) Cat# A11012, RRID:AB_141359) as
secondary antibody (1:500). Cell nuclei were counterstained with
4,6-diamidino-2-phenylindole (DAPI) (Roche Applied Science).
TUNEL assays to determine apoptosis were performed in toto using
the ApopTags Peroxidase In Situ Apoptosis Detection Kit (Milli-
pore) following the manufacturer’s instructions.
2.8. Quantitative real-time PCR analysis
qPCR assays were performed as previously described [36]. Total
RNA from zebraﬁsh embryos was isolated using the Trizol reagent
(Invitrogen, Life Technologies), treated with DNase I (New England
Biolabs) and 1 μg of total RNA was reverse transcribed with the
QuantiTect Reverse Transcription Kit (QiaGen). The primers used
to speciﬁcally amplify the DNA fragments are listed in Table S2.
These primers were designed with the Universal ProbeLibrary Assay
Design Center webtool from Roche Applied Science (https://www.
roche-applied-science.com/sis/rtpcr/upl/acenter.jsp?id¼030000),
or taken from [37]. RT-PCR experiments were performed following
the Minimum Information for Publication of Quantitative Real-
Time PCR Experiments (MIQE) guidelines [38]. The ampliﬁcation
reactions were carried out in 25 mL ﬁnal volume using Power SYBR
Green PCR Master Mix (Applied Biosystems, Life Technologies) andthe real-time polymerase chain reaction was performed using the
ABI Prism 7300 Applied Biosystems (Life Technologies). Ct values
were calculated with the SDS v1.3.1 software (Applied Biosystems,
Life Technologies) for each gene and the cDNA abundance of each
transcript was calculated relative to the expression of the house-
keeping gene eef1a1l1 using the REST-384© v2 software [39]. Also,
standard curves for each gene and negative controls (NTC: no
template control, and RNA: RNA which was not reverse tran-
scribed) were included in each PCR reaction. Experiments were
performed in triplicates and repeated four times. Statistical ana-
lysis was performed using Graph Pad Prism software.3. Results
3.1. Characterisation of GABAA receptor alpha 2 subunit (gabra2) in
the zebraﬁsh
The complete open reading frame of a gabra2 gene from zeb-
raﬁsh was cloned using standard methodology. Brieﬂy, the se-
quence of several partial ESTs were obtained from PubMed (Na-
tional Library of Medicine: http://www.ncbi.nlm.nih.gov/pubmed),
EMBL-EBI (http://www.ebi.ac.uk), ENSEMBL (http://www.ensembl.
org/index.html) and ZFIN (The Zebraﬁsh Model Organism Database;
http://zﬁn.org). CAP3 programme was used to assemble all these
ESTs in a putative cDNA sequence, and oligonucleotides were de-
signed to verify that the predicted cDNA was indeed expressed in
the zebraﬁsh. Given that part of the 5′ region was still missing, a 5′
RACE was performed, and ﬁnally the complete cDNA sequence of a
gabra2 gene was cloned (Fig. S1) in the pCR2.1 TOPO vector.
Genomic analysis revealed that this gabra2 gene (ENSEMBL ID:
ENSDARG00000070005) is located in chromosome 13 and com-
prises at least 10 exons which span along 31 Kbp (11998048–
12029410). There are another 3 gene predictions in chromosome
13 that match gabra2 gene (ENSDARG00000087129, EN-
SDARG00000091459 and ENSDARG00000034011) but they only
contain partial cDNAs. Up to now, it is not known whether these
predictions stand for tandem repeats or if they are assembly errors
which have not been manually curated so far.
The following protein domains have been identiﬁed in zebra-
ﬁsh Gabra2 using the SMART software (Fig. S1): (a) a signal pep-
tide (residues 1–27); (b) two regions with intrinsic disorder (re-
sidues 30–38 and 437–451); (c) a extracellular ligand binding
domain “Neur_chan_LBD” (PFAM accession number PF02931),
spanning amino acid residues 42 to 250; and (d) a transmembrane
domain “Neur_chan_memb” (PFAM accession number PF02932)
from residue 257 to 434, which contains four transmembrane α-
helices. These two latter domains are characteristic of the ligand-
gated ion channel superfamily, which comprises GABAA, nicotinic
acetylcholine, glycine, 5-HT3 serotonine and the ionotropic glu-
tamate receptors.
To determine if Gabra2 protein was conserved among the
evolutionary scale, the full-length sequences for Gabra2 protein in
different vertebrate species (mammals, amphibians and ﬁsh) were
obtained from TreeFam (Database accession number TF315453)
and aligned with MUSCLE from JalView (Fig. 1). The protein se-
quence is highly conserved (about 81% identity of all aligned se-
quences when compared to Gabra2 from zebraﬁsh, except for the
N-terminal signal peptide and three internal regions (residues
200–230, 350–370 and 390–420). In the case of Tetraodon, there
are some amino acid substitutions that could be due to sequencing
errors or to a poor sequence quality.
In an attempt to build a homological model, the predicted
zebraﬁsh Gabra2 protein sequence was submitted to Phyre2 to
generate alignments against proteins with published structures.
The human β3 homopentamer of GABAA receptor was the most
Fig. 1. Multiple sequence alignment of Gabra2 proteins from zebraﬁsh (dr – Danio rerio), human (hs – Homo sapiens), chimpanzee (pt – Pan troglodytes), cow (bt – Bos taurus),
mouse (mm – Mus musculus), rat (rn – Rattus norvegicus), xenopus (xt – Xenopus tropicalis) and two other ﬁsh species (tn – Tetraodon nigroviridis and ga – Gasterosteus
aculeatus). The initial set of sequences was obtained from the Treefam record of the family (Database accession number TF315453) and were automatically aligned using
MUSCLE and manually curated with JalView. The consensus sequence and conservation logo is shown below. The ClustalX colouring scheme is used and the four trans-
membrane regions are boxed. Note the high degree of sequence similarity for Gabra2 protein among all vertebrate species.
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(4COF PDB ID) [32], so that it was selected as template for
homology-based modelling, as the functional domains are con-
served. Residues 36–438 were modelled at 100% conﬁdence
(Fig. 2), so that the homological model of Gabra2 is consistent with
conservation of the overall three-dimensional structure between
these two proteins. Functional domains were annotated andbinding pockets were predicted by homology using clustalW
alignment with β3, α1, α2 and α6 subunits of human GABAA re-
ceptor. The transmembrane region displays the characteristic 4 α-
helices and the extracellular domain is mainly formed by β-sheets
connected by coiled regions. GABA binding loop D spans amino
acid residues Asp90 to Arg 96 and loop E spans Thr153 to Ala 164
(Fig. S1). GABA contacting amino acid residues Phe92, Arg94 (in
Fig. 2. Gabra2 homological model. (a) The 3D structure of zebraﬁsh gabra2 subunit was generated by homology modelling using the crystal structure of human GABRB3 (PDB
ID 4COF) as template. The protein structure is displayed as silhouette (rounded ribbon), and the Neur_chan_memb domain is coloured in blue, the Neur_chan_LBD domain in
green and the two regions with intrinsic disorder are left in white. In the extracellular domain, GABA binding loops D and E are coloured in yellow and benzodiazepine
binding loops A–C in orange. Side chains of important amino acid residues for ligand binding (either for GABA or for benzodiazepines) are shown and coloured by het-
eroatom. (b) GABA binding loops D (Asp90 – Arg 96) and E (Thr153 – Ala 164). Side chains of Phe92, Arg94 and Arg159 (amino acid residues known to interact with GABA)
are shown and coloured by element. (c) Benzodiazepine binding loops A–C (Trp122 – Lys132, Leu182 – Val194 and Thr224 – Ala242). Important amino acid residues for
ligand binding are shown and coloured by element. (d) Molecular surface of benzodiazepine binding site in GABRA2 subunit.
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domain. Benzodiazepine binding loop A spans amino acid Trp122
to Lys132, loop B Leu182 to Val194 and loop C Thr224 to Ala242
(Fig. S1); residues known to be important for benzodiazepine
binding [42,43] are fully conserved. Besides, the benzodiazepine
binding pocket was also predicted in this domain, which supports
the existence of a functional benzodiazepine binding domain.
3.2. gabra2 developmental expression
The spatio-temporal distribution of gabra2 was assayed by
wholemount in situ hybridisation on staged embryos which were
ﬁxed at different developmental stages (Fig. 3). To reveal the ex-
pression in some internal nuclei, 20 μm-thick sections were ob-
tained from the stained embryos. The onset of expression begins
before the end of the CNS segmentation period, as a diffuse ex-
pression in the neural tube was already seen at the stage of 11
somites, with stronger labelling at the presumptive mid- and
hindbrain areas, and at the tip of the tail. At 24 hpf the staining
was more intense and localised in several positive nuclei of the
brain and in the ﬂoor plate of the spinal cord. From 48 hpf until theend of the embryonic development, gabra2 expression was found
in the three brain regions (fore-, mid- and hindbrain), whereas the
positive labelling in the spinal cord was signiﬁcantly reduced.
3.3. Effects of dre-gabra2 knocking down on the development of the
CNS
Since it has been shown that the GABAergic system is involved
in the development of the CNS and in the maintenance of neural
stem cells, I wanted to determine the effects of the absence of a
functional Gabra2 protein. To achieve this, I have used a transla-
tion blocking morpholino to block the expression of gabra2 during
development in zebraﬁsh embryos. This morpholino did not sig-
niﬁcantly alter the expression levels of gabra3 (0.9170.02 fold
change at 24 hpf), which codes for another alpha subunit (α3)
closely related to gabra2. An up-regulation of c-fos mRNA levels
was observed in the morphant embryos (6.7270.75 fold change at
24 hpf and 2.4070.35 fold change at 48 hpf, as determined by
qPCR). Morpholino microinjection produced several macroscopic
defects, as smaller size of the embryos, changes in the morphology
of the brain and an increase in the size of the ventricles (Fig. S2).
Fig. 3. Developmental expression of gabra2 transcript. Analysis of dre-gabra2 expression by in situ hybridisation on wholemount embryos of (a) 11 somites, (b) 17 somites,
(c) 20 hpf, (d) 24 hpf, (e) 30 hpf, (f) 36 hpf, (g) 42 hpf, (h) 48 hpf, (i) 3 dpf and (j) 4 dpf. (a–j) lateral views are shown, where embryos are oriented with the anterior towards
the left. Inset of (g): ventral view of the head. (k–o) higher magniﬁcation images taken from 20 μm-thick sections that were obtained from stained embryos. (k) transverse
section (oriented dorsal up) of a 24 hpf embryo at the level of the spinal cord, where intense labelling is seen at the ﬂoor plate of the neural tube. (l) coronal section (oriented
anterior to the left) of an embryo of 48 hpf; staining is found lateral to the olfactory bulbs. (m and n) coronal sections (oriented anterior to the left) of embryos of 72 hpf,
where gabra2 expressing cells are located at surroundings of the olfactory bulbs (m), in the ganglion cell layer of the retina (m) and in some nuclei of the thalamus and of the
medulla oblongata (n). (o) coronal section (oriented anterior to the left) of an embryo of 4 dpf, where the olfactory epithelium is labelled with the gabra2 ISH probe.
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involved in CNS development.
3.4. gabra2 morphants display changes in the proliferation pattern
in the CNS
To determine whether knocking-down gabra2 expression af-
fects CNS development by disrupting the proliferation pattern,
phospho-histone 3 (Ser10) immunostaining (which speciﬁcally la-
bels cells on the M phase) was performed in control and in mor-
phant embryos of 24 and 48 hpf, both on wholemounts and on
cryosections. The results are summarised in Fig. 4. At 24 hpf, the
proliferation pattern was disorganised in gabra2 deﬁcient em-
bryos: in control embryos, positive cells were found along the
periventricular layer of the brain, and mitotic cells were more
widespread and dispersed in the morphants. Thus, the character-
istic pattern of proliferation in the brain was lost, and many mi-
totic cells were found scattered outside of the proliferation niches.
At 48 hpf, proliferation was more restricted to the periventricular
areas of the brain, which will harbour the stem-cell niches in the
adult CNS. At this stage, the morphant embryos seemed to recover
the wild-type pattern of proliferation, as the walls of the third
ventricle were clearly labelled; yet this labelling was more intense
in gabra2 deﬁcient embryos than in controls. In fact, experiments
performed on 14 μm-thick cryosections showed an increase in the
number of mitotically active cells along the midline of the teg-
mentum, in the retina and in the branchial arches. These results
indicate that knocking-down gabra2 expression might be altering
the proliferation of stem-cells and/or neural progenitors during
the embryonic development.
Each new cell can either keep its mitotic potential and remain
in an undifferentiated state (as stem or progenitor cell) or can exit
the cell cycle and differentiate into a specialized cell type. Cells
which fail to acquire a speciﬁc fate usually undergo programmedcell death; thus, an increase in apoptosis can compensate for over-
proliferation. To test whether this is the case in gabra2 deﬁcient
embryos, TUNEL assays have been performed (Fig. 5). Indeed, more
apoptotic nuclei were found in several brain areas which displayed
an excess of cells undergoing cell division. At 24 hpf, the hindbrain
region in the morphant embryos displayed a greater number of
TUNEL-positive cells as compared to controls. Apoptosis was
clearly reduced at 48 hpf, although some differences were ob-
served between controls and gabra2 deﬁcient ﬁsh: while apoptosis
is mostly absent in control cases, morpholino-injected embryos
showed intense labelling in the walls of the third ventricle, as well
as in some regions of the forebrain, namely the prectectum and
the tectum opticum.
3.5. Expression of several progenitor/differentiation markers in the
morphant CNS
To assess the developmental effects of the absence of a func-
tional Gabra2 protein, I have analysed the expression of several
genes known to be part of those signalling cascades that are in-
volved in the development of the CNS and neurogenesis. The
changes in mRNA levels have been determined by qPCR (Table 1)
and the differences in the expression pattern have been assayed by
in situ hybridisation (Figs. 6 and S3). The following genes were
studied: fgf8 (ﬁbroblast growth factor 8), neuroD (neurogenic dif-
ferentiation), notch1a (notch homologue 1a), pax2a (paired box
gene 2a), pax6a (paired box gene 2a), shh a (sonic hedgehog) and
wnt1 (wingless-type MMTV integration site family, member 1a).
fgf8 mRNA expression was increased at both stages, whereas the
opposite effect was seen for neuroD and pax2a. Interestingly,
notch1a and wnt1 mRNA expression was down-regulated at
24 hpf, but no signiﬁcant changes were observed at 48 hpf.
At 24 hpf, the expression pattern of fgf8 was more restricted in
gabra2 deﬁcient ﬁsh, as staining was localised at the presumptive
Fig. 4. Proliferation studies on gabra2 deﬁcient embryos. Phospho-histone 3 (Ser10) immunostaining [23] on zebraﬁsh control embryos and on embryos that were micro-
injected with gabra2 morpholino. In all cases embryos are oriented with the anterior towards the left and in (a–h) cell nuclei were counterstained with DAPI (blue). (a–d)
Images from wholemount immunostainings that were taken with a Leica M165FC Stereomicroscope a and b) Wholemount embryos of 24 hpf, where it can be seen that
proliferation pattern in the periventricular areas of the brain is disrupted in the morphant embryos. (c and d) At 48 hpf, the proliferative pattern is mainly restored, although
the labelling for the mitotic marker is increased in the periventricular areas of the mid- and hindbrain from morpholino-injected embryos. (e–h) Images from 14 μm thick
cryosections that were taken with an Olympus AX70 ﬂuorescence microscope. (e and f) sagittal views of the fore- and midbrain from embryos of 24 hpf; in control embryos,
positive cells are scattered throughout the ventral area of the brain, while mitotic cells show a more anterior and dorsal location in the morphant. (g and h) coronal sections
from embryos of 48 hpf; proliferative cells are found along the midline of the tegmentum and in the outermost external cell layer of the retina in the morpholino-injected
embryos, whereas control embryos display a more restricted pattern of proliferation in the CNS. (i–l) Higher resolution images of 14 μm thick cryosections taken with a Leica
confocal microscope. The periphery of the embryos, the eyes, lens, ventricles and yolk are outlined with dashed lines. (i and j) mid-sagittal section of the hindbrain from
embryos of 24 hpf, where it can be observed a dense distribution of positive cells along the wall of the ventricle in the morphant embryo. (k and l) coronal section of the
developing brain at 48 hpf. The gabra2 deﬁcient embryos display more labelled cells in the midline of the tegmentum and in the gill arches than controls. Labels: t:
tegmentum; v: ventricle; y: yolk: *: gill arches. Scale bars: e and f: 200 μm; g and h: 100 μm; (i–l): 75 μm.
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pattern were observed at 48 hpf. There was a strong a generalised
reduction of neuroD pattern of expression at 24 hpf, and at 48 hpf
the staining a the cerebellum was lost. notch1a labelling was
weaker in gabra2 morphants of 24 hpf, although the pattern of
expression remained unaltered; however, al 48 hpf there was a
stronger signal in the cephalic region, which might correspond to
the tendency observed in the qPCR results (the expression levels
were up-regulated, although they did not reach statistical sig-
niﬁcance). The expression pattern of pax2a became more localised
in morphant embryos of 24 hpf, as very strong labelling was found
a the anterior part of the forebrain, at the cerebellum and at the
hindbrain. At 48 hpf, the expression of pax2a, which is restricted to
the cerebellum and medulla oblongata, was weaker in gabra2
deﬁcient ﬁsh than in control embryos. At 24 hpf wnt1 labelling in
gabra2 morphants was clearly weaker, as all expression areas,
namely the dorsal midbrain, MHB, dorsal hindbrain and spinal
chord, seemed to be affected. At 48 hpf the staining was stronger
at the dorsal lateral hindbrain (that is, the walls of the third ven-
tricle), which might resemble the qPCR results (an up-regulation
of the levels of expression, although not statistically signiﬁcant).
The expression pattern of both pax6a and shh a remained un-
altered in gabra2 deﬁcient ﬁsh (Fig. S3), which is in accordance
with the obtained qPCR results for these two genes.3.6. Expression of gad1b in gabra2 deﬁcient ﬁsh
gad1b codes for the GABA-synthesising enzyme GAD67, so that
it can be used to cheque if the GABAergic neurotransmitter system
is altered in gabra2 injected ﬁsh. gad1b expression was reduced at
both at 24 hpf and 48 hpf, as determined by ISH (Fig. 7). At 24 hpf,
the staining was weaker at the mid- and hindbrain regions, while
at 48 hpf a moderate effect is observed: the labelling was parcially
lost, and it remained restricted to three paired nuclei: the olfactory
bulbs at the telencephalon (pretectum and tectum opticum) and
two paired nuclei at the hindbrain.
3.7. GABAergic drugs and proliferation during CNS development
To assess whether GABAergic activation can elicit changes in
the proliferation pattern during CNS development, zebraﬁsh em-
bryos were exposed to GABAergic drugs from 5 hpf to 24 hpf. The
following agents were used: 1 μM GABA; 1 μM muscimol, the
prototypic GABAA agonist [44]; and 100 μM bicuculline, a selective
GABA antagonist [45]. Proliferation was assessed by phospho-
histone 3 (Ser10) immunostaining on wholemounts, but no sig-
niﬁcant changes in the proliferative pattern were observed be-
tween control embryos and drug-treated groups (Fig. S4). TUNEL
assays (peroxidase staining) for detection of apoptotic cells were
Fig. 5. Apoptosis assays on gabra2 morphant embryos. TUNEL staining on gabra2 deﬁcient embryos of 24 hpf (a and b – dorsal views; e and f – lateral views) and 48 hpf (c and
d – dorsal views; g and h – 20 μm thick coronal sections). At 24 hpf, there is an increase in the number of apoptotic nuclei (which are positive for peroxidase labelling) in the
hindbrain region of morpholino-injected embryos [69.30715.52 apoptotic nuclei in control embryos as compared to 164.6736.87 in morphant embryos; * po0.05 as
determined by one sample t-test]. Apoptosis is reduced at 48 hpf when compared to morphants at 24 hpf (* po0.05 as determined by one sample t-test), although gabra2
deﬁcient ﬁsh display apoptotic cells in the walls of the third ventricle and in some regions of the forebrain. [36.8774.67 apoptotic nuclei in control embryos as compared to
77.0675.34 in morphant embryos; ** po0.01 as determined by one sample t-test]. (a–f) Embryos are oriented anterior towards the left and posterior towards the right. (g
and h) Orientation of embryos is anterior up; scale bar: 100 μm.
Table 1
Changes in the expression levels of several progenitor/differentiation markers in
dre-gabra2 deﬁcient ﬁsh.
gene 24 hpf 48 hpf
fgf8 1.4270.10* 1.5170.07**
neuroD 0.7070.08* 0.4970.10*
notch1a 0.5570.03*** 1.9270.50 (n.s.)
pax2a 0.6570.10* 0.7470.10 (n.s.)
pax6a 0.9270.08 (n.s.) 1.0070.10 (n.s.)
shh a 0.8470.10 (n.s.) 1.1570.16 (n.s.)
wnt1 0.4270.05** 1.2570.34 (n.s.)
Results represent the relative gene expression fold-changes of several genes known
to be part of signalling cascades that determine the development of the CNS in
gabra2 morpholino-injected embryos of 24 hpf and 48 hpf. Data shown are nor-
malised to dre-eef1a1l1. n.s. denotes p40.05 (not signiﬁcant);
* denotes po0.05;
** denotes po0.01;
*** denotes po0.001 (unpaired Student t-test, n¼4). 50 embryos were used for
each treatment and for each time point; the experiment was performed in tripli-
cates and repeated four times.
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was found in the forebrain of those embryos exposed to GABAergic
agents.4. Discussion
The interest in GABA signalling not only lies on the fact that it is
the main inhibitory neurotransmitter in the brain, but also it has
been related to several neurological disorders, as for example
epilepsy, anxiety, depression and schizophrenia [19,46]. Thus, the
study of GABAergic neurotransmitter system could bring novel
therapeutical approaches. Studies from knock-out mice revealed
that the GABAA receptor subtype containing α2 subunit could be
the target for novel antidepressant drugs [20]. Besides, GABA is
one of the mediators of ethanol effects in the CNS, and GABAA
receptors play a central role in the acute and chronic effects of
ethanol [17,47]. There is also a close link between the GABAergicand opioidergic systems, as opiates are able to inhibit GABA-
mediated synaptic transmission in certain brain regions [48].
Conversely, GABAergic neurons in the ventral tegmental area and
in the nucleus accumbens are involved in modulating the reinfor-
cing properties of opiates [49]. In fact, recent evidence shows that
selective agents targeting α2 and α3 subtypes of GABAA receptors
could be of great use as analgesics to treat chronic pain, as for
example neuropathic pain [50,51].
GABA is a rather ancient molecule, as it is also found in plants
and GABAergic signalling is already present in invertebrates [52].
The role of GABA is not only restricted to synaptic transmission,
but also it has been related to cell proliferation and differentiation
[53]. It has been reported that GABAA activation reduces the pro-
liferation of embryonic stem cells and neural crest stem cells in
mouse embryos, as autocrine / paracrine signalling causes cell
arrest in the S phase; as a consequence, there is a net reduction in
the stem cell progenies [13]. In fact, GABAA signalling helps to
regulate the stem cell niche [11]. Cortical development and neu-
rogenesis are also controlled by GABA and glutamate; these two
neurotransmitters are localised in the ventricular and sub-
ventricular zone, where the newborn cortical neurons arise.
GABAA and non-NMDA (mainly AMPA and kainate) receptor sig-
nalling are able to decrease DNA synthesis, while antagonists elicit
the opposite effect [54]. Therefore, alterations in GABAergic cir-
cuits during development have been related to several psychiatric
disorders, such as autism and schizophrenia [55]. For all these
reasons, I aimed to characterize the developmental effects of ga-
bra2 deﬁciency in the zebraﬁsh.
The molecular characterisation of Gabra2 has revealed that the
amino acid sequence of Gabra2 protein is highly conserved
throughout the evolutionary scale of vertebrates (80% percentage
of identity between mammalian, amphibian and ﬁsh homologues),
which may serve as evidence for functional conservation. Besides,
the crystal structure of Gabra subunits has not been experimen-
tally solved yet, so it was necessary to generate a homological
model of Gabra2. The high degree of domain conservation and
structural similarity among neurotransmitter-gated ion channels
allowed me to build the 3D structure of zebraﬁsh Gabra2, and this
Fig. 6. Effect of the knocking down of gabra2 gene on the expression pattern of several developmental markers. ISH studies were conducted on control embryos (a, c, e, g, i, k, m,
o, q and s) and on gabra2morphants (b, d, f, h, j, l, n, p, r and t) at 24 hpf (a, b, e, f, i, j, m, n, q and r) and 48 hpf (c, d, g, h, k, l, o, p, s and t) to establish the expression pattern of
several markers known to be involved in CNS development: (a–d) fgf8; (e–h) neuroD; (i–l) notch1a; (m–p) pax2a; and (q–t) wnt1. Note that the expression patterns of all
genes are altered in gabra2 deﬁcient ﬁsh, and that the mid- and hindbrain regions are more affected than the forebrain. Embryos are oriented with the anterior towards the
left and posterior towards the right. (a, b, k, l and o–t) dorsal views; (c–j, m and n) lateral views.
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and with the clustalw alignment. Two binding domains are iden-
tiﬁed in the same regions as in GABRB3, and key amino acids for
GABA and benzodiazepine binding are present. These features
suggest that the intermolecular interactions of α2 (namely, with
zebraﬁsh β and γ subunits) may be largely conserved, so that
zebraﬁsh Gabra2 protein may display the same functionality as its
human homologue. Therefore, results obtained in zebraﬁsh can be
extrapolated to higher vertebrates, thus yielding reliable estima-
tions about the role of GABA in vertebrate development.
gabra2 expression is detected at early stages of embryonic de-
velopment in the main subdivisions of the CNS, which may sug-
gest that gabra2 is playing a role in development, by controlling
proliferation and/or differentiation. As development proceeds,
staining becomes more restricted to certain areas of the fore- andmidbrain. A morpholino-based approach allowed me to block the
expression of gabra2 gene and to analyse its effect in CNS devel-
opment. Although morpholinos have been extensively used to
speciﬁcally knock-down gene expression in zebraﬁsh, it has been
recently stated that this technique shows certain limitations, and a
certain degree of off-target effects cannot be ruled out [56]. The
morphant embryos were viable and did not show a strong mac-
roscopic phenotype, as they only display a smaller body size and a
modest swelling of the brain ventricles; this weak phenotype
could be due to the existence of compensatory mechanisms in the
early embryo. However, the pattern of proliferation was clearly
disrupted in all brain regions, as dividing cells were found in
anomalous locations. An increase in apoptotic cells was observed
at 24 hpf mainly in the hindbrain. At 48 hpf stronger labelling was
found for both mitotic and apoptotic markers at the walls of the
Fig. 7. Expression pattern of gad1b on gabra2 deﬁcient ﬁsh. The expression pattern of gad1b (GABA-synthesising enzyme GAD67)-GABAergic marker-was assayed by ISH on (a
and c) control and b and d) gabra2 morphant embryos at 24 hpf (a and b) and 48 hpf (c and d). Note the reduction of the areas of expression (as determined by a decrease in
the stained area) found for this gene at both stages. Dorsal views are shown, in which embryos are oriented with the anterior towards the left and posterior towards the
right.
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abnormally dividing may be unable to acquire a speciﬁc cell fate,
and hence they undergo programmed cell death. It is not known
whether this aberrant proliferation may result in depletion of
stem- or progenitor cells in the mature CNS, as it has been pre-
viously reported [57,58]. Taken together, our results indicate that
gabra2 might be involved in shaping the proliferating micro-
environment in the early embryo.
The process of differentiation into specialized cell types takes
place during the embryonic development, and is tightly regulated
by signalling cascades. The absence of a functional Gabra2 seems
to affect the development of the mid- and hindbrain regions. It is
well known that the isthmic organiser signalling at the MHB is
essential for the proper development and regionalisation of the
mid- and hindbrain. notch1, pax2, fgf8 and wnt1 are the major
players in controlling MHB establishment and positioning [59].
Hence I have analysed if these signalling pathways are altered in
gabra2 deﬁcient embryos. notch1 is involved in the regulation of
the stem-cell niche, both during the embryonic development as
well as in the adult organism, as it controls the balance between
the stem-cell self renewal, proliferation and progenitor differ-
entiation [60]. notch1 also plays a role in boundary formation and
restricts Ffg8 signalling from the organiser [61]. pax2, together
with wnt1 and fgf8, is involved in the maintenance of the MHB
isthmic organiser [62]. In fact, pax2 is the inducer of fgf8 [59] and
Fgf8 signalling from the isthmic organiser determines the ante-
roposterior neural patterning in the midbrain and cerebellum [63].
wnt1 regulates mid- and hindbrain (mainly cerebellum) develop-
ment, and is involved in establishing the MHB [64]. These genes
are mis-expressed in gabra2 morphants, as their transcriptional
level is altered and their pattern of expression is different from
those found in control embryos. In fact, it seems that the staining
is more restricted, and stronger labelling is found at the border
between mesencephalon and cerebellum. Hence, it is possible that
gabra2 might be playing a role in the embryonic development of
the mid- and hindbrain. Interestingly, neurodevelopmental ab-
normalities have also been related to misexpression of the neuron-speciﬁc potassium/chloride cotransporter 2 (KCC2), as KCC2 over-
expression perturbs neuronal differentiation and development in
mouse [65] and zebraﬁsh embryos [66]. In mice, early KCC2 ex-
pression impairs proper axon maturation in the hindbrain and
spinal cord [65], and in zebraﬁsh KCC2 interacts with the actin
cytoskeleton to modulate neuronal differentiation, although the
active form of this chloride exporter is not required for this in-
teraction [66].
Phospho-histone 3 immunostaining indicates that there are
more proliferating cells in the morphant CNS, so it is possible that
fewer cells are undergoing differentiation towards a neuronal
lineage. Therefore I have also analysed the expression of neuroD:
this proneural gene is implicated in early neuronal determination,
and is essential for the differentiation of granule cells in the cer-
ebellum and hippocampus [67,68]. Indeed, neuroD expression is
down-regulated in gabra2 deﬁcient embryos.
pax6, which is a highly conserved transcription factor, plays a
key role in CNS development, as for example it is involved in eye
development and in the patterning of the neural tube. pax6 also
regulates proliferation and differentiation in the neurogenic ni-
ches, namely the subgranular zone of the dentate gyrus in the
hippocampus and in the subventricular zone [69]. Besides, shh is a
diffusible morphogenwhich is involved in the control of numerous
developmental processes, from rather early events (as it is the case
of the dorso-ventral patterning of the neural tube) to the pro-
liferation of neural precursors during embryonic development and
in the adult organism [70]. shh and pax6 regulate the balance
between glutamategic and GABAergic neurogenesis [71]. However,
no clear changes in the expression of these two genes were ob-
served in the morphant embryos. This result can be explained by
the presence of redundant signalling pathways or of compensatory
mechanisms.
On a further step I have evaluated if the GABAergic neuro-
transmitter system is affected in gabra2 deﬁcient ﬁsh. gad1 (GABA-
synthesising enzyme GAD67) expression, a marker for GABAergic
cells, was signiﬁcantly reduced in the morphant embryos; this
outcome may indicate that the generation of GABAergic cells is
V. Gonzalez-Nunez / Biochemistry and Biophysics Reports 3 (2015) 190–201200reduced in gabra2 morpholino-injected ﬁsh. Interestingly, gad1
expression is reduced in the pretectum and tectum opticum, and
these two areas are known to harbour a rich population og GABA-
positive cells [72].
I also wanted to check whether GABAergic drugs can induce
changes in proliferation and in apoptosis. I have tested the effects
of GABA, muscimol (a prototypic GABAA agonist [44]) and bicu-
culline (a selective GABA antagonist [45]). None of them were able
to modify the pattern of cell proliferation at 24 hpf. However, re-
peated exposure to GABA and muscimol can induce tolerance, by
promoting down-regulation of the receptors [73], and/or even at
the mRNA level [74]. This possibility, as well as receptor desensi-
tization after prolongued agonist exposure, cannot be ruled out in
order to explain the apparent lack of effect of GABAergic drugs on
CNS development.5. Conclusion
gabra2 codes for the GABAA receptor alpha-2, and it amino acid
sequence is highly conserved among vertebrate evolution, which
may serve as evidence for functional conservation. Our results
indicate that gabra2 might be involved in shaping the proliferating
niches in the early embryo. Besides, gabra2 may also interact with
those signalling pathways that control proliferation, differentia-
tion and neurogenesis during the embryonic development, prin-
cipally in the differentiation of the mesencephalon and cere-
bellum. However, considering the weak phenotype observed for
the morphant embryos, it can be concluded that gabra2 is not a
major player in the CNS development, or maybe a compensatory
mechanism could overcome the absence of a functional gabra2.
These ﬁndings will help to understand the role of neuro-
transmitter systems during CNS development.Declarations of interest
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